COMMUNIQUÉS West-GlobeNewswire
-
Life Sciences Week 2024: Advancing Innovation, Investment, and Collaboration in Alberta’s Life Sciences Sector
23/09/2024 - 19:10 -
La quadrithérapie à base de DARZALEX® (daratumumab) reçoit un avis favorable de la part du CMUH pour les patients atteints d’un myélome multiple nouvellement diagnostiqué et éligibles à une greffe
23/09/2024 - 19:34 -
SAFE Group - Report d’audience d’examen des plans de redressements au 18 octobre 2024
23/09/2024 - 20:20 -
Comprehensive Urology Studies ED Injections with Shockwave Therapy for Penile Girth Enhancement
23/09/2024 - 21:34 -
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database
23/09/2024 - 22:05 -
BioVie Inc. Announces Proposed Public Offering
23/09/2024 - 22:05 -
DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE
23/09/2024 - 22:30 -
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
23/09/2024 - 22:30 -
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
22/09/2024 - 16:00 -
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)
21/09/2024 - 00:36 -
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
21/09/2024 - 00:36 -
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
21/09/2024 - 10:10 -
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
21/09/2024 - 10:15 -
Financière de Tubize - Transparency notification
20/09/2024 - 08:00 -
213,285 Orion Corporation A shares converted into B shares
20/09/2024 - 08:30 -
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
20/09/2024 - 11:00 -
Inbiome, developing a new PCR technology capable of simultaneous identification of hundreds of bacterial pathogens in a single test, welcomes Professor Dr. Carl Wittwer to its Advisory Board
20/09/2024 - 11:03 -
CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques secondairement progressive non active
20/09/2024 - 11:30 -
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
20/09/2024 - 11:30
Pages